Danuglipron free base

• CAS: 2230198-02-2
• Catalog Number: ACM2230198022
• Category: Agonists
• Molecular Weight: 555.61
• Molecular Formula: C31H30FN5O4
• Description: Danuglipron, also known as PF-06882961 is a potent, orally bioavailable agonist of the glucagon-like peptide-1 receptor agonist (GLP-1R). WO 2019148044 (2019).
• Synonyms: Danuglipron; PF-06882961; PF 06882961; PF06882961; Danuglipron free base
• IUPAC Name: (S)-2-((4-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid
• Canonical SMILES: OC(C1=CC=C(N=C(CN2CCC(C3=NC(OCC4=CC=C(C#N)C=C4F)=CC=C3)CC2)N5C[C@H]6OCC6)C5=C1)=O
• InChI: InChI=1S/C31H30FN5O4/c32-25-14-20(16-33)4-5-23(25)19-41-30-3-1-2-26(35-30)21-8-11-36(12-9-21)18-29-34-27-7-6-22(31(38)39)15-28(27)37(29)17-24-10-13-40-24/h1-7,14-15,21,24H,8-13,17-19H2,(H,38,39)/t24-/m0/s1
• InChI Key: HYBAKUMPISVZQP-DEOSSOPVSA-N
• Solubility: Soluble in DMSO
• Appearance: Solid powder
• Shelf Life: >3 years if stored properly
• Storage: Dry, dark and at 0-4 °C for short term (days to weeks) or -20 °C for long term (months to years).
• Alternative CAS: 2230198-02-2 (free acid); 2230198-03-3 (tris)
• Biological Target: Danuglipron (PF-06882961), a non-peptide agonist, activates the canonical G protein signaling activity only in the Glucagon-like; peptide-1 (GLP-1) receptor with Trp33ECD.
• Drug Formulation: This drug may be formulated in DMSO
• Elemental Analysis: C, 67.01; H, 5.44; F, 3.42; N, 12.61; O, 11.52
• Exact Mass: 555.2282
• HS Tariff Code: 2934.99.9001
• In Vitro Activity: For example, a methylene-linked oxetane increased potency ~100-fold relative to the methyl substituent of 5, leading to the; identification of PF-06882961, which is a full agonist (EC50 = 13 nM) in the CS cAMP assay (Fig. 3A, Table S2). PF-06882961 also; incorporates a nitrile replacement for the chloride in the benzyl ether region, which served to reduce CLint in HLM as well as in; human hepatocytes (Table S4).; Reference: J Med Chem. 2022 Jun 23;65(12):8208-8226. https://pubmed.ncbi.nlm.nih.gov/35647711/
• In Vivo Activity: Intravenous infusion of PF-06882961 during the IVGTT led to an increase in insulin secretion and the rate of glucose disappearance; (K-value) (Fig. 5B-D). Enhancement of glucose-stimulated insulin secretion by PF-06882961 was concentration-dependent and was; also observed following oral dosing with similar efficacy when compared to administration by IV infusion (Fig. 5E). Once-daily; administration of PF-06882961 for 2 days also inhibited food intake compared to vehicle-treated monkeys (Fig. 5F).; Reference: J Med Chem. 2022 Jun 23;65(12):8208-8226. https://pubmed.ncbi.nlm.nih.gov/35647711/
• Shipping: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
• Stock Solution Storage: 0-4 °C for short term (days to weeks), or -20 °C for long term (months).